1
Sakon Kiyoyuki, Sakagami Masahiro, Makino Yuji, Suzuki Yoshiki, Kobayashi Hideki: Ultrafine powder for inhalation and production thereof.. Teijin, August 24, 1994: EP0611567-A1 (85 worldwide citation)

An ultrafine powder for inhalation to be transferred mainly to the lower airway, which comprises a drug and hydroxypropylcellulose and/or hydroxypropylmethylcellulose and wherein the particles having diameters in the range of 0.5-10 mu m account for 80 wt.% or above.


2
Sato Haruya, Yamamoto Keiji, Suzuki Kokichi, Ikeda Masahiro, Sakagami Masahiro, Taniguchi Makoto: Method of modifying protein. Drug Delivery System Inst, August 7, 1996: EP0725145-A1 (11 worldwide citation)

A physiologically active protein (including a fused protein comprising the same and a peptide bonded thereto through an amide linkage) is improved in the adaptability to a medicine by modifying the protein through the action of a transglutaminase on the same and an amino group donor having a polyeth ...


3
Okuno Takayuki, Kouyama Naoki, Sakagami Masahiro: (Ja) npy y5受容体拮抗作用を有するアミン誘導体, (En) Amine derivative having npy y5 receptor antagonist activity. Shionogi &, Okuno Takayuki, Kouyama Naoki, Sakagami Masahiro, TAKAYAMA Hirotsugu, November 8, 2007: WO/2007/125952 (11 worldwide citation)

(EN) Disclosed is a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, or a solvate of any of them. (I) In the formula, R1 represents an optionally substituted lower alkyl group; Y represents -S(O)n- (wherein n is 1 or 2) or -CO-; R2 represents a hydrogen or a ...


4
SAKAGAMI Masahiro, ARAKI Hitomi, HASHIZUME Hiroshi, YARI Hiroshi, TAKAYA Kenji: [ja] NPY Y5受容体拮抗作用を有するピペリジンおよびピロリジン誘導体, [fr] DÉRIVÉS DE LA PIPÉRIDINE ET DE LA PYRROLIDINE DOTÉS DUN ANTAGONISME POUR LES RÉCEPTEURS NPY Y5, [en] PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM. SHIONOGI &, SAKAGAMI Masahiro, ARAKI Hitomi, HASHIZUME Hiroshi, YARI Hiroshi, TAKAYA Kenji, TANAKA Mitsuo, September 10, 2010: WO/2010/101246 (7 worldwide citation)

[en] Disclosed are novel piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism. Specifically disclosed are a compound represented by formula (I), a pharmaceutically acceptable salt of the same or a solvate thereof. In formula (I), A represents substituted or unsubstituted monocycl ...


5
Okuno Takayuki, Kouyama Naoki, Sakagami Masahiro: (Ja) npy y5受容体拮抗作用を有するアミン誘導体およびその用途, (En) Amine derivative having npy y5 receptor antagonist activity and use thereof. Shionogi &, Okuno Takayuki, Kouyama Naoki, Sakagami Masahiro, TAKAYAMA Hirotsugu, April 30, 2009: WO/2009/054434 (6 worldwide citation)

(EN) Disclosed is an appetite suppressant or anti-obesity agent containing a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, or a solvate of any of them. (In the formula, R1 represents an optionally substituted lower alkyl; Y represents -S(O)n- (wherein n i ...


6
Okuno Takayuki, Kouyama Naoki, Sakagami Masahiro: Amine derivative having npy y5 receptor antagonist activity. Shionogi & Co, January 21, 2009: EP2017261-A1 (3 worldwide citation)

This invention provides a compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally substituted lower alkyl, Y is -S(O)n- wherein n is 1 or 2, or -CO-, R 2 is hydrogen or lower alkyl, R 7 is hydrogen or lower alkyl, X is lower alkylene, lower alken ...


7
Sakon Kiyoyuki, Sakagami Masahiro, Makino Yuji, Suzuki Yoshiki, Kobayashi Hideki: Poudre particulaire ultrafine pour inhalation et methode de production, Ultrafine particle powder for inhalation and method for production thereof. Teijin, MCFADDEN FINCHAM, December 23, 1993: CA2115065 (2 worldwide citation)

An ultrafine particle powder for inhalation to be delivered mainly to a lower airway, containing specific cellulose lower alkyl ethers and a medicament, at least 80% of the powder having a particle size in the range of 0.5 to 10 �m.


8
YOSHIDA HIROSHI, TONOGAKI KEISUKE, SAKAGAMI MASAHIRO, TAKAYA KENJI: CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM, CYCLOHEXANDERIVAT MIT NPY-Y5-REZEPTORANTAGONISMUS, DÉRIVÉ DE CYCLOHEXANE PRÉSENTANT UN ANTAGONISME DU RÉCEPTEUR NPY Y5. SHIONOGI & CO, January 11, 2012: EP2404896-A1 (2 worldwide citation)

The present invention discloses novel cyclohexane derivatives having NPY Y5 receptor antagonistic activity. Specifically, the present invention discloses a compound represented by the formula (I), or a pharmaceutically acceptable salt or a solvate thereof: wherein A is substituted or unsubstituted a ...


9
SAKAGAMI MASAHIRO, ARAKI HITOMI, HASHIZUME HIROSHI, YARI HIROSHI, TAKAYA KENJI: PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM, PIPERIDIN- UND PYRROLIDINDERIVATE MIT NPY-Y5-REZEPTORANTAGONISMUS, DÉRIVÉS DE LA PIPÉRIDINE ET DE LA PYRROLIDINE DOTÉS DUN ANTAGONISME POUR LES RÉCEPTEURS NPY Y5. SHIONOGI & CO, January 11, 2012: EP2404902-A1 (1 worldwide citation)

The present invention discloses novel piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonistic activity. Specifically, the present invention discloses a compound represented by the formula (I), a pharmaceutically acceptable salt or a solvate thereof: wherein A is substituted or uns ...


10
SAKAGAMI MASAHIRO, HASHIZUME HIROSHI, TANAKA SATORU, OKUNO TAKAYUKI, YARI HIROSHI, TONOGAKI KEISUKE, KOUYAMA NAOKI: [fr] COMPOSÉ POSSÉDANT UNE ACTIVITÉ D ANTAGONISTE DU RÉCEPTEUR Y5 DU NPY, [de] VERBINDUNG MIT NPY-Y5-REZEPTORANTAGONISTENWIRKUNG, [en] COMPOUND HAVING NPY Y5 RECEPTOR ANTAGONIST ACTIVITY. SHIONOGI & CO, February 2, 2011: EP2280000-A1

[en] This invention provides a compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is substituted or unsubstituted alkyl or the like, R 2 is hydrogen or substituted or unsubstituted alkyl, Ring A is monocyclic or bicyclic aromatic heterocycle, R 3 is subst ...



Click the thumbnails below to visualize the patent trend.